Drug intelligence / Profile preview

aflibercept + sirolimus

Development stage: Unknown
Lead developer: Santen Pharmaceutical
Modality: Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravitreal

Overview

A combination therapy consisting of aflibercept (a vascular endothelial growth factor inhibitor) and sirolimus (also known as rapamycin). This combination has been investigated for treating persistent, exudative age-related macular degeneration in patients who continue to experience fluid accumulation despite previous anti-VEGF treatments. The therapy involves alternating monthly intravitreal injections of sirolimus and aflibercept.

Targets

mTOR (Mammalian target of rapamycin kinase)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on aflibercept + sirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aflibercept + sirolimus.

Explore the full profile